/* */ PELVIPHARM - Spinal cord injury-induced neurogenic detrusor overactivity
Receive our news

 

Spinal cord injury-induced neurogenic detrusor overactivity

Modelís advantageS

  • The most commonly utilised and highly informative model of a central lesion with respect to lower urinary tract function
  • used for the evaluation of drugs targeting neurogenic detrusor overactivity (NDO) but also overactive bladder whatever its etiology
  • useful to investigate the effect of mechanisms known to act on C-fiber afferents
  • useful to investigate an effect on the external urethral sphincter activity

SPECIES

rat

Pathophysiological featureS

  • Mimics the voiding patterns of patients with neurogenic detrusor overactivity due to spinal cord injury
  • Display neurogenic detrusor overactivity characterized by non-voiding contractions during the filling phase with increased maximal micturition pressure and increased micturition duration.
  • Reduced voiding efficiency and large residual urine volume associated with detrusor-sphincter dyssynergia
  • Bladder hypertrophy
  • Increase in bladder afferent nerve activity, in particular through C-fibers
  • BBB score impairment altered locomotor activity (reduced BBB score)
Figure 1: Representative cystometrograms in conscious 3 weeks SCI and sham rats. Arrows indicate the voiding contractions. Neurogenic detrusor overactivity occured in the SCI rat but not in sham rats. (Pelvipharm, internal data).
Figure 1: Representative cystometrograms in conscious 3 weeks SCI and sham rats. Arrows indicate the voiding contractions. Neurogenic detrusor overactivity occured in the SCI rat but not in sham rats. (Pelvipharm, internal data).



Summarized methodology

A T7-T8 laminectomy is performed and the spinal cord is cut between T7 and T8 vertebrae. A sterile gelform sponge is placed between the cut ends of the spinal cord.

Neurogenic detrusor overactivity progressively develops over time until 3-4 weeks where it is stabilized.

Figure 2: Complete transection between vertebral T7-T8.
Figure 2: Complete transection between vertebral T7-T8.
Related Pelvipharm bibliography
Broqueres-You, D. et al. Basic & Clinical Pharmacology & Toxicology, 107 (Suppl. 1), 192 (WorldPharma 2010)

Behr-Roussel, D. et al. J Urol (2010) : 183(4),supl1:e391 (AUA, 2010)

Broqueres-You, D. et al. J Urol (2010) : 183(4),supl1:e76-e77 (AUA, 2010)

Behr-Roussel, D. et al. Eur Urol Suppl (2010) : 9(2):73 (EAU, 2010)

Broqueres-You, D. et al. Eur Urol Suppl (2010) : 9(2):112 (EAU, 2010)

Broqueres-You, D. et al. Neurourol Urodyn (2009) : 28(7):695 (ICS, 2009)

Broqueres-You, D. et al. J Urol Abstract (AUA, 2008) : 179(4) : 348-349
SITEMAP
TEL +331 704 293 39
FAX + 331 704 295 10
LEGAL